5.1955
8.53%
-0.4845
アフターアワーズ:
5.55
0.3545
+6.82%
Pluri Inc (PLUR) 最新ニュース
(PLUR) Proactive Strategies - Stock Traders Daily
Plurilock’s Behavioral Biometrics: Next-Gen Cybersecurity with Scott Meyers - The Deep Dive
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Plurilock Security joins forces with cloud platform for data protection - Mugglehead
Ever After Foods receives $10 million investment - Food Business News
Former CrowdStrike Director Reveals Plurilock’s Potential - The Deep Dive
(PLUR) Technical Pivots with Risk Controls - Stock Traders Daily
Pluri Unveils Proprietary 3D Cell Expansion Technology - Contract Pharma
Cyber Warfare: Ex-CIA Officer Warns of New Global Conflict, With Bryan Cunningham of Plurilock Security - The Deep Dive
Pluri (NASDAQ:PLUR) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Critical Review - American Banking and Market News
(PLUR) Trading Advice - Stock Traders Daily
Critical Survey: Tevogen Bio (NASDAQ:TVGN) versus Pluri (NASDAQ:PLUR) - Defense World
Spanish seafood processors slam plant-based seafood labeling practices; Steakholder Foods signs MoU with Sherry Herring - SeafoodSource
Spanish seafood processors slam plant-based seafood labeling practices; Tender Food products now in Clover locations - SeafoodSource
Pluri Inc. faces potential Nasdaq delisting over equity shortfall - Investing.com
Pluri Inc. faces potential Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
400% Stock Surge: What’s Next for Plurilock Security? | Ali Hakimzadeh - The Deep Dive
Pluri enters deal to manufacture Kadimastem’s AstroRx for ALS - ALS News Today
Pluri signs tech transfer, manufacturing agreement with Kadimastem - TipRanks
Pluri’s CDMO To Manufacture Kadimastem’s Cell Therapy Candidates - Contract Pharma
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates - Morningstar
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates - StockTitan
(PLUR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Joe Sexton: Enhancing Plurilock’s Vision with Decades of Experience - The Deep Dive
Contrasting Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - American Banking and Market News
Plurilock Appoints Palantir Senior Advisor To Company’s Industry Advisory Council - The Deep Dive
Critical Comparison: Pluri (NASDAQ:PLUR) & Relay Therapeutics (NASDAQ:RLAY) - Defense World
Pluri (NASDAQ:PLUR) Trading 0.3% Higher - Defense World
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs - Business Wire
Pluri Inc partners to boost global vegetable supply - Investing.com India
Pluri Inc partners to boost global vegetable supply By Investing.com - Investing.com Canada
Morgan Stanley raises TSMC shares target on strong demand outlook By Investing.com - Investing.com India
Seagate stock target raised, maintains Neutral stance on financial performance By Investing.com - Investing.com India
Strategic Agreement Sparks Market Interest In Pluri (PLUR) Stock - State Reviewer
Pluri Inc partners to boost global vegetable supply - Investing.com
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply - StockTitan
Pluri announces proof of concept agreement with an agriculture corporation - TipRanks
BioCentriq Enhances Partnership With Pluristyx - Contract Pharma
Pluri Inc. appoints new CFO as current officer resigns By Investing.com - Investing.com South Africa
Pluri Inc. appoints new CFO as current officer resigns By Investing.com - Investing.com
Freshworks director Zachary Nelson sells $238,855 in company stock By Investing.com - Investing.com UK
Pluri Inc. Announces CFO Transition and New Appointment - TipRanks
Pluri Inc. appoints new CFO as current officer resigns - Investing.com
(PLUR) Investment Report - Stock Traders Daily
UBS Offshore Accounts: Sebi's Half Baked Case Against Indian Billionaires - BW Businessworld
Regulus reports positive ADPKD trial results at 3 mg/kg dose By Investing.com - Investing.com
Pluri subsidiary Ever After Foods secures $10M strategic investment - MSN
Pluri Inc partners to boost global vegetable supply By Investing.com - Investing.com
Dr. Michal Sheleg on a Novel Immunotherapy Platform for Solid Tumor Treatment - DocWire News
Pluri: Several Opportunities Across Different Sectors - Seeking Alpha
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food - EIN News
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges - StockTitan
Trend Tracker for (PLUR) - Stock Traders Daily
Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve
Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight - Yahoo Finance
NIAID funds second year of Pluri's radiation therapy studies By Investing.com - Investing.com India
NIAID funds second year of Pluri's radiation therapy studies - Investing.com India
NIAID funds second year of Pluri's radiation therapy studies By Investing.com - Investing.com
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract - GlobeNewswire Inc.
3D Cell-Expansion Technology Revolutionizing Industries: Interview with Lior Raviv, Chief Technology Officer at Pluri - TechBullion
大文字化:
|
ボリューム (24 時間):